(S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoic acid | CAS:666832-71-9

We serve (S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoic acid CAS:666832-71-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
(S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoic acid

Synonyms:
(S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoic acid
Trifluoroacetyl L-Tert-Leucine
N-Trifluoroacetyl L-Tert-Leucine
 
Molecular Formula: C8H12F3NO3
Molecular weight:227.18100
 
Uses: Intermediates of Paxlovid PF-07321332 2628280-40-8, which is used as a drug to treat the COVID-19.
 
 
 



Contact us for information like (S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Intermediates of 2628280-40-8 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Intermediates of 2628280-40-8 Use and application,Intermediates of Paxlovid technical grade,usp/ep/jp grade.


Related News: Featured APIs: Production capacity continues to expand, targeted patents expire. Original research drugs: industry entry barriers are high, performance stability and certainty are high.GGDYKDDDDK manufacturer Featured APIs: Production capacity continues to expand, targeted patents expire. Original research drugs: industry entry barriers are high, performance stability and certainty are high.N-methyl-1-(4-methylphenyl)-5-(trifluoromethyl)pyrazole-4-carboxamide supplier The injection has previously proven to be as effective as standard daily pills with three active ingredients when administered monthly and also once every two months.RNA (Hepatitis C virus isolate MYAN-54-1 gene NS5 fragment) vendor The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG’s pharmaceutical business within the Corden Pharma platform. The companies’ goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed.